Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 23936.0%.

  • Lyra Therapeutics' EBITDA Margin fell 178595900.0% to 23936.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 3529.66%, marking a year-over-year increase of 101635800.0%. This contributed to the annual value of 4021.63% for FY2023, which is 332500.0% up from last year.
  • Per Lyra Therapeutics' latest filing, its EBITDA Margin stood at 23936.0% for Q3 2025, which was down 178595900.0% from 4063.93% recorded in Q2 2025.
  • Over the past 5 years, Lyra Therapeutics' EBITDA Margin peaked at 830.11% during Q4 2024, and registered a low of 129318.18% during Q4 2022.
  • For the 5-year period, Lyra Therapeutics' EBITDA Margin averaged around 17264.93%, with its median value being 4221.8% (2024).
  • Per our database at Business Quant, Lyra Therapeutics' EBITDA Margin plummeted by -1242934600bps in 2022 and then soared by 1189647600bps in 2023.
  • Quarter analysis of 5 years shows Lyra Therapeutics' EBITDA Margin stood at 5024.72% in 2021, then plummeted by -2474bps to 129318.18% in 2022, then surged by 92bps to 10353.42% in 2023, then soared by 108bps to 830.11% in 2024, then crashed by -2983bps to 23936.0% in 2025.
  • Its last three reported values are 23936.0% in Q3 2025, 4063.93% for Q2 2025, and 4670.49% during Q1 2025.